These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 29019118)
1. Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Konstantinidis IT; Chouliaras K; Levine EA; Lee B; Votanopoulos KI Ann Surg Oncol; 2017 Dec; 24(13):3825-3830. PubMed ID: 29019118 [TBL] [Abstract][Full Text] [Related]
2. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715 [TBL] [Abstract][Full Text] [Related]
3. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study. Cascales-Campos PA; López-López V; Muñoz-Casares FC; Feliciangeli E; Torres Melero J; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Gil J Surg Oncol; 2016 Jun; 25(2):111-6. PubMed ID: 27312037 [TBL] [Abstract][Full Text] [Related]
4. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
5. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy. Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223 [TBL] [Abstract][Full Text] [Related]
6. More Synchronous Peritoneal Disease but Longer Survival in Younger Patients with Carcinomatosis from Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Solomon D; DeNicola NL; Feferman Y; Bekhor E; Reppucci ML; Feingold D; Aycart SN; Magge DR; Golas BJ; Labow DM; Sarpel U Ann Surg Oncol; 2019 Mar; 26(3):845-851. PubMed ID: 30643994 [TBL] [Abstract][Full Text] [Related]
7. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583 [TBL] [Abstract][Full Text] [Related]
8. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Elderly: Is It Reasonable? A Meta-Analysis. Gagnière J; Veziant J; Pereira B; Pezet D; Le Roy B; Slim K Ann Surg Oncol; 2018 Mar; 25(3):709-719. PubMed ID: 29282602 [TBL] [Abstract][Full Text] [Related]
9. Preoperative Nutrition Status and Postoperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Reece L; Dragicevich H; Lewis C; Rothwell C; Fisher OM; Carey S; Alzahrani NA; Liauw W; Morris DL Ann Surg Oncol; 2019 Aug; 26(8):2622-2630. PubMed ID: 31123932 [TBL] [Abstract][Full Text] [Related]
10. Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Chambers LM; Chalif J; Yao M; Chichura A; Morton M; Gruner M; Costales AB; Horowitz M; Chau DB; Vargas R; Rose PG; Michener CM; Debernardo R Gynecol Oncol; 2021 Aug; 162(2):368-374. PubMed ID: 34083027 [TBL] [Abstract][Full Text] [Related]
11. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study. Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495 [TBL] [Abstract][Full Text] [Related]
12. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406 [TBL] [Abstract][Full Text] [Related]
13. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716 [TBL] [Abstract][Full Text] [Related]
14. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Doud AN; Randle RW; Clark CJ; Levine EA; Swett KR; Shen P; Stewart JH; Votanopoulos KI Ann Surg Oncol; 2015 May; 22(5):1645-50. PubMed ID: 25120249 [TBL] [Abstract][Full Text] [Related]
15. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640 [TBL] [Abstract][Full Text] [Related]
16. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures. Foster JM; Sleightholm R; Patel A; Shostrom V; Hall B; Neilsen B; Bartlett D; Smith L JAMA Netw Open; 2019 Jan; 2(1):e186847. PubMed ID: 30646202 [TBL] [Abstract][Full Text] [Related]
17. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients. Piso P; Nedelcut SD; Rau B; Königsrainer A; Glockzin G; Ströhlein MA; Hörbelt R; Pelz J Ann Surg Oncol; 2019 Jan; 26(1):148-154. PubMed ID: 30456672 [TBL] [Abstract][Full Text] [Related]
18. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement. Franssen B; Tabrizian P; Weinberg A; Romanoff A; Tuvin D; Labow D; Sarpel U Ann Surg Oncol; 2015 May; 22(5):1639-44. PubMed ID: 25216604 [TBL] [Abstract][Full Text] [Related]
19. Safety and quality outcomes in peritoneal surface malignancy patients: developing a national center for excellence in Colombia. Arias F; Herrera-Almario G; Pozo ME; Londoño-Schimmer E; Otero JM; Cardona A; Cortes N; Mora M Ann Surg Oncol; 2015 May; 22(5):1733-8. PubMed ID: 25239004 [TBL] [Abstract][Full Text] [Related]
20. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes. Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]